sur Vogenx, Inc. (NASDAQ:VOGX)
Vogenx Appoints Richard Gorman as Chief Commercial Officer
Vogenx, Inc. (Nasdaq: VOGX), a company focused on developing treatments for metabolic and gastrointestinal diseases, has appointed Richard Gorman as Chief Commercial Officer, effective October 12, 2026. Gorman, who served on the board since 2022, will resign from his board position. The company plans to find a new independent director shortly.
In his new role, Gorman will spearhead Vogenx's commercial operations and corporate strategy, focusing on market development for post-bariatric hypoglycemia and gastroparesis. Gorman's responsibilities will also include business development, such as partnership and licensing strategies.
CEO James Green highlighted Gorman's significant influence on Vogenx's strategic direction since 2022, emphasizing the need for commercial strategies to advance mizagliflozin's development. With over 30 years of experience, Gorman's vast expertise includes numerous successful product launches, notably in the metabolic disease sector.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Vogenx, Inc.